06:35 AM EDT, 03/19/2025 (MT Newswires) -- HUTCHMED ( HCM ) and Innovent Biologics said late Tuesday that a phase II/III clinical trial of fruquintinib in combination with sintilimab as a second-line treatment for renal cell carcinoma in China has met its primary endpoint of progression free survival.

The combination also showed improvements in secondary endpoints, including objective response rate and response duration, the companies said.

Renal cell carcinoma is a type of kidney cancer.